Cargando…

Global Distribution and Prevalence of Hepatitis C Virus Genotypes

Hepatitis C virus (HCV) exhibits high genetic diversity, characterized by regional variations in genotype prevalence. This poses a challenge to the improved development of vaccines and pan-genotypic treatments, which require the consideration of global trends in HCV genotype prevalence. Here we prov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Messina, Jane P, Humphreys, Isla, Flaxman, Abraham, Brown, Anthony, Cooke, Graham S, Pybus, Oliver G, Barnes, Eleanor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2015
Materias:	Viral Hepatitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303918/ https://www.ncbi.nlm.nih.gov/pubmed/25069599 http://dx.doi.org/10.1002/hep.27259

Ejemplares similares

Characterization of the Specificity, Functionality, and Durability of Host T‐Cell Responses Against the Full‐Length Hepatitis E Virus
por: Brown, Anthony, et al.
Publicado: (2016)

Chronic hepatitis C viral infection subverts vaccine‐induced T‐cell immunity in humans
por: Kelly, Christabel, et al.
Publicado: (2016)

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)
por: Lawitz, Eric, et al.
Publicado: (2016)

Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus
por: van de Ven, Nikolien, et al.
Publicado: (2015)

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study
por: Kwo, Paul, et al.
Publicado: (2016)

Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection
por: Robinson, Mark W., et al.
Publicado: (2015)

Flunarizine prevents hepatitis C virus membrane fusion in a genotype‐dependent manner by targeting the potential fusion peptide within E1
por: Perin, Paula M., et al.
Publicado: (2015)

IFITM1 is a tight junction protein that inhibits hepatitis C virus entry,
por: Wilkins, Courtney, et al.
Publicado: (2013)

Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme
por: Hézode, Christophe, et al.
Publicado: (2017)

Estimating the Net Contribution of Interleukin-28B Variation to Spontaneous Hepatitis C Virus Clearance
por: di Iulio, Julia, et al.
Publicado: (2011)

A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection
por: Kao, Jia‐Horng, et al.
Publicado: (2016)

Activated Macrophages Promote Hepatitis C Virus Entry in a Tumor Necrosis Factor-Dependent Manner
por: Fletcher, Nicola F, et al.
Publicado: (2014)

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis
por: Kumada, Hiromitsu, et al.
Publicado: (2015)

High antiviral activity of NS5A inhibitor ABT‐530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection
por: Poordad, Fred, et al.
Publicado: (2016)

Type I interferon rapidly restricts infectious hepatitis C virus particle genesis
por: Meredith, Luke W, et al.
Publicado: (2014)

Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials
por: Brown, Ashley, et al.
Publicado: (2019)

The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment
por: Kandeel, Amr, et al.
Publicado: (2016)

Hepatitis E virus and fulminant hepatitis–a virus or host-specific pathology?
por: Smith, Donald B, et al.
Publicado: (2015)

Paracrine Signals From Liver Sinusoidal Endothelium Regulate Hepatitis C Virus Replication
por: Rowe, Ian A, et al.
Publicado: (2014)

Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub‐Saharan Africa: Systematic review and meta‐analysis
por: Surial, Bernard, et al.
Publicado: (2020)

Chronic Hepatitis E is associated with cholangitis
por: Beer, Andrea, et al.
Publicado: (2019)

Branched-chain amino acids reduce hepatic iron accumulation and oxidative stress in hepatitis C virus polyprotein-expressing mice
por: Korenaga, Masaaki, et al.
Publicado: (2015)

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals
por: Martin, Natasha K, et al.
Publicado: (2013)

Over time evaluation of glycaemic control in direct‐acting antiviral‐treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis
por: Cacciola, Irene, et al.
Publicado: (2021)

Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies
por: Yao, Betty B., et al.
Publicado: (2020)

Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan
por: Chen, Chi‐Yi, et al.
Publicado: (2021)

Spatial epidemiology of hepatitis C virus infection in Egypt: Analyses and implications
por: Cuadros, Diego F, et al.
Publicado: (2014)

Chronic Hepatitis C Virus (HCV) Disease Burden and Cost in the United States
por: Razavi, Homie, et al.
Publicado: (2013)

Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt
por: Benova, Lenka, et al.
Publicado: (2015)

microRNA changes in liver tissue associated with fibrosis progression in patients with hepatitis C
por: Van Keuren‐Jensen, Kendall R., et al.
Publicado: (2015)

Are non‐invasive fibrosis markers for chronic hepatitis B reliable in sub‐Saharan Africa?
por: Desalegn, Hailemichael, et al.
Publicado: (2017)

Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles
por: Oliveira, Catarina, et al.
Publicado: (2017)

Treatment induced clearance of hepatitis E viruses by interferon‐lambda in liver‐humanized mice
por: Sari, Gulce, et al.
Publicado: (2021)

Predicting hepatitis B e Antigen seroconversion after pregnancy—The SydPregScore
por: Thilakanathan, Cynthuja, et al.
Publicado: (2022)

DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection
por: Burza, Maria Antonella, et al.
Publicado: (2015)

Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C
por: Tsochatzis, Emmanuel A, et al.
Publicado: (2014)

Effect of Immune Pressure on Hepatitis C Virus Evolution: Insights From a Single-Source Outbreak
por: Merani, Shahzma, et al.
Publicado: (2011)

Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection
por: Lattimore, Sam, et al.
Publicado: (2014)

Expression of scavenger receptor‐AI promotes alternative activation of murine macrophages to limit hepatic inflammation and fibrosis
por: Labonte, Adam C., et al.
Publicado: (2016)

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence
por: Poordad, Fred, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_m94pqhj0igccujhonkmtorljif